GlobalData on MSN19h
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks
After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...
AARP18h
Is It Too Soon to Diagnose Alzheimer’s in People With No Symptoms?
Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...
Aged Care Insite7h
TGA doubles down on rejection of Alzheimer’s drug
Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...